Local Cerebral Glucose Utilisation Following Indoleamine‐ and Piperazine‐Containing 5‐Hydroxytryptamine Agonists

Jj, Grome; Am, Harper

doi:10.1111/j.1471-4159.1986.tb12933.x

Cited by 35 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[14][15][16][17]19 Serotonin agonists decrease brain glucose metabolism in animals. 49 Increased thalamic volumes in psychotropic-naïve patients with OCD may be consistent with prior reports of hypermetabolism and increased regional cerebral blood flow in the thalamus of adult patients with OCD 6,8,10,50 that decreased after SSRI intervention. 21 This may, in part, explain the finding of Jenike et al 23 of no thalamic volumetric differences between adult patients with OCD and controls.…”

Section: Commentsupporting

confidence: 87%

Decrease in Thalamic Volumes of Pediatric Patients With Obsessive-compulsive Disorder Who Are Taking Paroxetine

Gilbert¹,

Moore²,

Keshavan³

et al. 2000

Arch Gen Psychiatry

243

129

View full text Add to dashboard Cite

Our findings provide new evidence of thalamic abnormalities in pediatric OCD and further suggest that paroxetine treatment may be paralleled by a reduction in thalamic volume. These reductions may, however, not be specific to paroxetine treatment and could be due to a more general treatment response, and/or spontaneous improvement in symptoms. Our findings are preliminary given the small sample size and our inability to measure discrete thalamic nuclei.

show abstract

Section: Commentsupporting

confidence: 87%

Decrease in Thalamic Volumes of Pediatric Patients With Obsessive-compulsive Disorder Who Are Taking Paroxetine

Gilbert¹,

Moore²,

Keshavan³

et al. 2000

Arch Gen Psychiatry

243

129

View full text Add to dashboard Cite

show abstract

“…Sokoloff et al 1977;Dam etal. 1982;Dam and London 1984;Grome and Harper 1986). In many studies, only rough descriptions of the localization of measuring fields are given as frontal, parietal, occipital, sulcal and suprarhinal (e.g.…”

Section: Introductionmentioning

confidence: 99%

Local cerebral glucose utilization in the neocortical areas of the rat brain

1990

View full text Add to dashboard Cite

The neocortex of the rat brain can be subdivided into regions of different local cerebral glucose utilization (LCGU). However, only a few neocortical areas can be delineated by differences in mean LCGUs between neighbouring areas. These area borders correspond exactly with cytoarchitectonically defined borders found in adjacent Nissl-stained preparations. On the other hand, nearly all of the architectonically defined area borders are also recognizable in the LCGU pictures, if differences in laminar distribution patterns of LCGU are taken into account. Furthermore, interareal differences in mean LCGU mainly reflect changes in layer IV, whereas layers II-III and V-VI show nearly identical LCGU values in all neocortical areas of the rat brain. The primary sensory areas exhibit the highest LCGU in layer IV, while the primary motor cortex shows a high LCGU in layer V. As the cytoarchitectonically defined pattern of the cortex is generally corroborated by the regional and laminar LCGU distribution, anatomical, metabolic and functional aspects of cortical architecture are associated.

show abstract

“…There are strong similarities between this pattern of alteration in metabolic activity and that obtained following the administration of other serotonin agonist agents (cf. Freo et al, 1993a;Freo, 1996;Grome and Harper, 1986). Treatment with the serotonin-5HT 2 agonist, m-CPP, at doses that reduced locomotor activity, for example, also depressed functional activity in basal ganglia, dorsal and ventral striatum, raphe nuclei, amygdala, and cortical regions (Freo et al, 1992), as did the administration of quipazine (Freo et al, 1993b).…”

Section: Discussionmentioning

confidence: 94%

Local cerebral metabolic effects of the novel cocaine analog, WF-31: Comparisons to fluoxetine

Porrino

Miller

Hedgecock

et al. 1997

Synapse

View full text Add to dashboard Cite

The effects of the acute administration of the selective serotonin uptake inhibitor, fluoxetine, on rates of local cerebral glucose utilization in rats were compared to those of the novel cocaine analog, [2beta-propanoyl-3beta-(4-isopropylphenyl)-tropane, WF-31, which has greater affinity for serotonin than dopamine transporters, using the quantitative autoradiographic 2-[14C]deoxyglucose method. Locomotor activity was assessed simultaneously. Fluoxetine administration resulted in dose-dependent decreases in locomotor behavior, as well as widespread reductions in rates of metabolic activity in brain areas including raphe nuclei, dorsal and ventral striatum, amygdala, hippocampus, limbic cortex, and thalamus. These effects were largely concentrated in brain regions containing high densities of serotonin transporters as revealed by in vitro autoradiography. In contrast, the acute administration of WF-31 produced more discrete changes in metabolic activity that were localized within the raphe nuclei and in portions of the hippocampal formation. Blockade of WF-31's dopaminergic effects by pretreatment with the antagonist, alpha-flupenthixol, resulted in a pattern of metabolic changes that closely resembled that observed with fluoxetine. These data suggest that the alterations in functional activity produced by both fluoxetine and WF-31 are largely the result of actions on serotonergic systems.

show abstract

Local Cerebral Glucose Utilisation Following Indoleamine‐ and Piperazine‐Containing 5‐Hydroxytryptamine Agonists

Cited by 35 publications

References 31 publications

Decrease in Thalamic Volumes of Pediatric Patients With Obsessive-compulsive Disorder Who Are Taking Paroxetine

Decrease in Thalamic Volumes of Pediatric Patients With Obsessive-compulsive Disorder Who Are Taking Paroxetine

Local cerebral glucose utilization in the neocortical areas of the rat brain

Local cerebral metabolic effects of the novel cocaine analog, WF-31: Comparisons to fluoxetine

Contact Info

Product

Resources

About